In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Hold rating on Rallybio, with a price target of $1.00. The company’s shares closed yesterday at $0.56.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Clark-Gartner covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Dianthus Therapeutics, and AbbVie. According to TipRanks, Clark-Gartner has an average return of 17.8% and a 67.37% success rate on recommended stocks.
Currently, the analyst consensus on Rallybio is a Moderate Buy with an average price target of $1.00.
The company has a one-year high of $1.24 and a one-year low of $0.22. Currently, Rallybio has an average volume of 546.2K.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Semiconductor%20Chip%20by%20Gorodenkoff%20via%20Shutterstock.jpg)
/Oracle%20Corp_%20office%20logo-by%20Mesut%20Dogan%20via%20iStock.jpg)
